STEINHART RICHARD I (Chief Financial Officer) sold 20.7% of their position (6.84K shares) of BIOXCEL THERAPEUTICS, INC. on the open market
Open‑market sale worth $7.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/22/2026ACC: 0001104659-26-065838
Officer· Chief Financial Officer
Since Nov 2018
-6.84K
Net shares
Net seller
$7.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
17.50K acquired · 24.34K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+17.50K
Price / share
—
Trade value
—
% of position
111.9%
5/4/2026
15.64K→33.15K
Common Stock
Direct
Shares
−6.84K
Price / share
$1.08
Trade value
$7.43K
% of position
20.7%
5/20/2026
33.15K→26.30K
Total
Net shares
+10.65K
Net value
-$7.43K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/4/2026 | M · Option Exercise | +17.50K | — | — | 111.9% | 15.64K | 33.15K |
| Common Stock Direct | 5/20/2026 | S · Sale | −6.84K | $1.08 | $7.43K | 20.7% | 33.15K | 26.30K |
| Total | +10.65K | -$7.43K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
17.50K shares
Shares
−17.50K
Strike price
Held after
52.50K
Exercisable
—
5/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock17.50K shares | 5/4/2026 | M · Option Exercise | −17.50K | — | 52.50K |